Overview

N Acetylcystene in Treatment of Radiotherapy Induced Oral Mucositis in Oral Cancer Patients

Status:
COMPLETED
Trial end date:
2025-03-09
Target enrollment:
Participant gender:
Summary
Background: Radiotherapy appears to be one of the most effective therapies in head and neck tumors, however, there are a lot of complications related to it. Oral Mucositis is one of the most common complications following radiotherapy. There are currently huge unmet needs for management of oral mucositis. It causes severe pain, reduces food intake and affects quality of life of the head and neck cancer patients .N-acetylcysteine (NAC) is a glutathione precursor which has an antioxidant property and protects against radiation therapy-induced free radical damage. NAC reduces the production of inflammatory markers which leads to decrease inflammation, treats oral mucositis and enhances quality of life of the patient. Aim: To evaluate the effectiveness of N-acetylcysteine and its formulated nanoparticles in treatment of radiotherapy induced oral mucositis in oral cancer patients .
Phase:
NA
Details
Lead Sponsor:
Hams Hamed Abdelrahman
Treatments:
Acetylcysteine